ArticleThe American journal of case reports2026
Acute Hemorrhagic Necrotizing Encephalopathy in a COVID-19 Patient With a Response to Intravenous Immunoglobulin Therapy.
Article in The American journal of case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Acute hemorrhagic necrotizing encephalopathy (AHNE) is a rare, immune-mediated condition that follows viral infection and has a poor prognosis. Previously reported cases of AHNE have described a favorable clinical response to intravenous immunoglobulin (IVIG) therapy combined with corticosteroids. This report describes the case of a 67-year-old Bahraini man with AHNE associated with Coronavirus Disease-19 (COVID-19) with a response to IVIG therapy. CASE REPORT We report a 67-year-old Bahraini man with type 2 diabetes, hypertension, and a prior hemi-colectomy, presenting with acute febrile encephalopathy and a positive SARS-CoV-2 test result. The patient presented with confusion and rapid neurological decline. A magnetic resonance imaging (MRI) scan demonstrated symmetrical hemorrhagic lesions in the bilateral thalami, pons, and periventricular white matter, consistent with AHNE. Despite high-dose intravenous methylprednisolone, his condition worsened. Subsequent intravenous immunoglobulin therapy (IVIG) led to gradual neurological improvement. After a 4-month hospital stay with intensive rehabilitation, he was discharged ambulatory with minimal assistance, residual spastic dysarthria, and pyramidal weakness. A follow-up brain MRI scan showed marked lesion regression. CONCLUSIONS This case highlights the need to consider AHNE in adults with unexplained acute encephalopathy, especially amid recent viral infections like SARS-CoV-2. The patient's improvement with IVIG draws attention to its potential therapeutic role in selected adults, while also revealing the limitations of pediatric prognostic tools such as Acute Necrotizing Encephalopathy severity score (ANE-SS) in this population. Further research is needed to clarify AHNE pathophysiology, define adult-specific outcome predictors, and establish standardized diagnostic and treatment protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.